We are live on ! Find out more
RVPH

REVIVA PHARMA HLDGS INC

Delisted

RVPH was delisted on the 13th of May, 2026.

42 hedge funds and large institutions have $3.52M invested in REVIVA PHARMA HLDGS INC in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,404% more call options, than puts

Call options by funds: $576K | Put options by funds: $23K

0.8% less ownership

Funds ownership: 1.49%0.69% (-0.8%)

9% less funds holding

Funds holding: 4642 (-4)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

35% less capital invested

Capital invested by funds: $5.44M → $3.52M (-$1.93M)

Holders
42
Holders Change
-4
Holders Change %
-8.7%
% of All Funds
0.55%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
9
Reduced
10
Closed
10
Calls
$576K
Puts
$23K
Net Calls
+$553K
Net Calls Change
-$1.68M
Name Holding Trade Value Shares
Change
Change in
Stake
DP
1
Diadema Partners
New Jersey
$924K -$97.1K -11,427 -8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$710K +$50.6K +5,956 +7%
Millennium Management
3
Millennium Management
New York
$631K +$94.8K +11,159 +15%
PAP
4
Persistent Asset Partners
Hong Kong
$219K -$20.1K -2,364 -7%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$206K +$47.2K +5,552 +25%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$193K +$182K +21,358 +441%
Jane Street
7
Jane Street
New York
$84.1K +$97K +11,407 New
Renaissance Technologies
8
Renaissance Technologies
New York
$79.8K +$92K +10,830 New
Simplex Trading
9
Simplex Trading
Illinois
$63K -$23.6K -2,777 -24%
ECM
10
EMC Capital Management
Texas
$48K +$212 +25 +0.4%
State Street
11
State Street
Massachusetts
$46.7K
XT
12
XTX Topco
Cayman Islands
$37K +$7.84K +922 +22%
Lido Advisors
13
Lido Advisors
California
$36.7K +$42.3K +4,982 New
Northern Trust
14
Northern Trust
Illinois
$26.3K
SIS
15
Sound Income Strategies
Florida
$23.6K
Cetera Investment Advisers
16
Cetera Investment Advisers
Illinois
$22.1K +$25.5K +3,000 New
BlackRock
17
BlackRock
New York
$21.2K
Focus Partners Wealth
18
Focus Partners Wealth
Massachusetts
$19.5K
SSA
19
Schonfeld Strategic Advisors
New York
$17.8K -$33.5K -3,942 -62%
LFG
20
Larson Financial Group
Missouri
$12.9K +$14.9K +1,750 New
Creative Planning
21
Creative Planning
Kansas
$11.8K
AQR Capital Management
22
AQR Capital Management
Connecticut
$10.3K +$11.9K +1,400 New
VPIM
23
Vanguard Personalized Indexing Management
California
$8.81K -$1.39K -164 -12%
TRCT
24
Tower Research Capital (TRC)
New York
$8.26K +$8.92K +1,050 +1,479%
Two Sigma Investments
25
Two Sigma Investments
New York
$8.03K -$2.75K -323 -23%

RVPH Hedge Fund Activity: Q3 2025 in Review

42 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q3 2025, worth a combined $3.52M — down 35% from $5.44M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of RVPH and 7 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 9 added.

The largest buyer was Susquehanna International Group, adding an estimated $182K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.03M sold.

  • 42 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q3 2025, down from 46 in Q2 2025.
  • Funds reported $3.52M of REVIVA PHARMA HLDGS INC stock for Q3 2025, down 35% quarter-over-quarter.
  • 7 funds opened new REVIVA PHARMA HLDGS INC positions in Q3 2025 and 10 closed out, a net change of -3 holders.
  • The largest REVIVA PHARMA HLDGS INC buyer in Q3 2025 was Susquehanna International Group, an estimated $182K added.
  • The largest REVIVA PHARMA HLDGS INC seller in Q3 2025 was Armistice Capital, an estimated $1.03M sold.

Based on aggregated 13F filings for Q3 2025.